IPSEN (OTCMKTS:IPSEY) Shares Gap Down - What's Next?

Key Points

• IPSEN shares experienced a significant gap down, opening at $32.02 after closing at $34.07, reflecting a 6.0% decrease in value.
• The stock has a fifty-day moving average of $33.10, indicating a potential continuing downward trend if it does not rebound.
• IPSEN is a biopharmaceutical company focusing on treatments in oncology, neuroscience, and rare diseases, with several products currently in clinical trials.

IPSEN (OTCMKTS:IPSEY - ) gapped down before the market opened on Friday . The stock had previously closed at $34.07, but opened at $32.02. IPSEN shares last traded at $32.02, with a volume of 137 shares.

IPSEN Trading Down 6.0%

The company has a fifty day moving average of $33.10 and a two-hundred day moving average of $30.49.

About IPSEN

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.